Changes

Due to Ivermectin being out of patent, there is very little profit in selling it as a treatment. However, in December 2020 Merck signed a $356 million dollar supply deal with NIAID. They would supply 60,000-100,000 doses of a new experimental COVID-19 treatment pill called "MK-7110" (formerly known as "CD24Fc"). OncoImmune originally created the drug, but Merck bought out that company for $425,000,000, acquiring rights to the drug. [[Bill Gates]]' International Aids Vaccine Initiative agreed to distribute this new drug throughout developing nations. The undertaking was later discontinued.<ref name="The real Anthony Fauci">Kennedy, R. F. (2022). Chapter 8. The real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. essay, Skyhorse Publishing.</ref> <ref>https://www.merck.com/news/merck-to-discontinue-development-of-mk-7110-for-covid-19/</ref>

Due to Ivermectin being out of patent, there is very little profit in selling it as a treatment. However, in December 2020 Merck signed a $356 million dollar supply deal with NIAID. They would supply 60,000-100,000 doses of a new experimental COVID-19 treatment pill called "MK-7110" (formerly known as "CD24Fc"). OncoImmune originally created the drug, but Merck bought out that company for $425,000,000, acquiring rights to the drug. [[Bill Gates]]' International Aids Vaccine Initiative agreed to distribute this new drug throughout developing nations. The undertaking was later discontinued.<ref name="The real Anthony Fauci">Kennedy, R. F. (2022). Chapter 8. The real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. essay, Skyhorse Publishing.</ref> <ref>https://www.merck.com/news/merck-to-discontinue-development-of-mk-7110-for-covid-19/</ref>

Merck also hoped to make massive profit from another new drug they were working on, Molnupiravir. This was a newly developed protease inhibitor, which utilizes an identical mechanism to stop viruses, but as a new drug, could be patented. The Defense Threat Reduction Agency provided $10,000,000 in 2013 and 2015 to Emory University, to develop Molnupiravir as a veterinary drug for horses, to treat equine encephalitis. NIAID contributed $19,000,000, and then handed off the drug to Merck and Miami-based Ridgeback Biotherapeutics. They immediately set to work getting ready to sell the new drug as a COVID-19 treatment, worth billions of dollars. It was slated to sell for $700 per treatment course. However, there were major safety concerns, even among some of its co-developers at Emory University. There were fears that Molnupiravir would cause serious side affects, including birth defects. It is sold under the brand name "Lagevrio." <ref name="The real Anthony Fauci">Kennedy, R. F. (2022). Chapter 8. The real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. essay, Skyhorse Publishing.</ref>

Merck also hoped to make massive profit from another new drug they were working on, Molnupiravir. This was a newly developed protease inhibitor, which utilizes an identical mechanism to stop viruses, but as a new drug, could be patented. The Defense Threat Reduction Agency provided $10,000,000 in 2013 and 2015 to Emory University, to develop Molnupiravir as a veterinary drug for horses, to treat equine encephalitis. NIAID contributed $19,000,000, and then handed off the drug to Merck and Miami-based Ridgeback Biotherapeutics. They immediately set to work getting ready to sell the new drug as a COVID-19 treatment, worth billions of dollars. It was slated to sell for $700 per treatment course. However, there were major safety concerns, even among some of its co-developers at Emory University. There were fears that Molnupiravir would cause serious side affects, including birth defects. It is sold under the brand name "Lagevrio."<ref name="The real Anthony Fauci">Kennedy, R. F. (2022). Chapter 8. The real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. essay, Skyhorse Publishing.</ref>

 

As Merck was working on their Ivermectin knock-off, Pfizer also joined the race with their own protease inhibitor, "PF-07321332" (Nirmatrelvir). This drug was also very similar in mechanism and function to Ivermectin, to the extent that it was given the nickname "Pfizermectin." Like Molnupiravir, this drug was designed to be a patent-protected replacement for Ivermectin, so price gouging would be possible.<ref name="The real Anthony Fauci">Kennedy, R. F. (2022). Chapter 8. The real Anthony Fauci: Bill Gates, Big Pharma, and the Global War on Democracy and Public Health. essay, Skyhorse Publishing.</ref>

Experimental vaccines were also a major competitor to Ivermectin. Multiple pharmaceutical companies were seeking emergency approval for their new products, but that can only be granted if there are no pre-existing treatments which are effective and approved as safe. It was therefore of utmost importance that any other pre-existing medication be found ineffective, so their emergency use of the vaccines could be approved.

Experimental vaccines were also a major competitor to Ivermectin. Multiple pharmaceutical companies were seeking emergency approval for their new products, but that can only be granted if there are no pre-existing treatments which are effective and approved as safe. It was therefore of utmost importance that any other pre-existing medication be found ineffective, so their emergency use of the vaccines could be approved.